ArticleMolecular psychiatry2025
Resting-state functional connectivity in anxiety disorders: a multicenter fMRI study.
Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03208400 (Exposure Treatment in Anxiety Disorders), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exposure Treatment in Anxiety Disorders: Proof of Principle for an a Priori Response Prediction Approach
Who cites it
21 citing papers in PubMed.
- Effect of a single dose of lorazepam on resting state functional connectivity in healthy adults.Brain imaging and behavior · 2025Trial
- Elevated Galvanic Skin Response and Associated Brain Network Patterns in Youth at High Familial Risk for Bipolar Disorder.JAACAP open · 2026Article
- Discrimination of generalized anxiety and major depressive disorders by machine learning of resting-state functional MRI.BMC psychiatry · 2026Article
- Transient cerebellum-related network disruption characterizes postoperative cognitive changes after dominant hemisphere subtemporal meningioma resection.Acta neurochirurgica · 2026Article
- Nociceptin/orphanin FQ receptor agonism attenuates behavioral and neural responses to conditioned aversive stimuli.Translational psychiatry · 2026Article
- Anxiety disorders alter cognitive-motor integration during visuomotor adaptation and retention.Experimental brain research · 2026Article
- Longitudinal Changes in Infant Attention-Related Brain Networks and Fearful Temperament.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- Botulinum Toxin for Chronic Migraine: Beyond Headache Reduction and Toward Possible Cognitive Benefits.Toxins · 2026Review
- Sex-Based Mechanisms of Stress-Induced Alcohol-Seeking.Behavioral sciences (Basel, Switzerland) · 2026Article
- Cerebellar Tissue Properties Alterations in Fibromyalgia: A T1w/T2w Ratio Study.Human brain mapping · 2026Article
- From synapse to system: mechanistic pathways of neural signaling dysfunction in psychiatric disorders.Frontiers in cell and developmental biology · 2026Review
- Investigating biotypes and neural characteristics among anxiety, depression, and comorbidity via a novel noisy label learning method.Psychoradiology · 2026Article
- A novel deep learning model for objective quantification of generalized anxiety disorder severity using EEG functional connectivity.Frontiers in psychiatry · 2026Article
- Brainwide Analysis of Functional Connectivity Patterns in Specific Phobia and Its Treatment.Biological psychiatry global open science · 2025Article
- Functional Magnetic Resonance Imaging-Based Analysis of Functional Connectivity in Chronic Stress: A Comparison of Stress-Induced and Recovery States.Brain sciences · 2025Article
- Association between anxiety disorder, anxiolytic drugs, and risk of incident Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Glymphatic Function as a Prognostic Biomarker in Prolonged Disorders of Consciousness.CNS neuroscience & therapeutics · 2025Article
- Resolving heterogeneity in first-episode and drug-naive major depressive disorder based on individualized structural covariance network: evidence from the REST-meta-MDD consortium.Psychological medicine · 2025Article
- Event cache: An independent component in working memory.Science advances · 2025Article
- Schismogenesis in anxiety spectrum disorders: a biopsychosocial perspective.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
Abstract
Anxiety disorders (AD) are associated with altered connectivity in large-scale intrinsic brain networks. It remains uncertain how much these signatures overlap across different phenotypes due to a lack of well-powered cross-disorder comparisons. We used resting-state functional magnetic resonance imaging (rsfMRI) to investigate differences in functional connectivity (FC) in a cross-disorder sample of AD patients and healthy controls (HC). Before treatment, 439 patients from two German multicenter clinical trials at eight different sites fulfilling a primary diagnosis of panic disorder and/or agoraphobia (PD/AG, N = 154), social anxiety disorder (SAD, N = 95), or specific phobia (SP, N = 190) and 105 HC underwent an 8 min rsfMRI assessment. We performed categorical and dimensional regions of interest (ROI)-to-ROI analyses focusing on connectivity between regions of the defensive system and prefrontal regulation areas. AD patients showed increased connectivity between the insula and the thalamus compared to controls. This was mainly driven by PD/AG patients who showed increased (insula/hippocampus/amygdala-thalamus) and decreased (dorsomedial prefrontal cortex/periaqueductal gray-anterior cingulate cortex) positive connectivity between subcortical and cortical areas. In contrast, SAD patients showed decreased negative connectivity exclusively in cortical areas (insula-orbitofrontal cortex), whereas no differences were found in SP patients. State anxiety associated with the scanner environment did not explain the FC between these regions. Only PD/AG patients showed pronounced connectivity changes along a widespread subcortical-cortical network, including the midbrain. Dimensional analyses yielded no significant results. The results highlighting categorical differences between ADs at a systems neuroscience level are discussed within the context of personalized neuroscience-informed treatments. PROTECT-AD's registration at NIMH Protocol Registration System: 01EE1402A and German Register of Clinical Studies: DRKS00008743. SpiderVR's registration at ClinicalTrials.gov: NCT03208400.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.